A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved ...
In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...
The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...
Feline Lower Urinary Tract Disease — Symptoms include straining to urinate, urinating small amounts frequently, painful ...
Ocugen’s updated fair value estimate has shifted from US$10.36 to US$11.57, putting recent analyst work into a slightly higher price target range. Analysts are tying this move to fresh research around ...
Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio, Inc.
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving ...
Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6bn.
Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results